Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials

CO Stiller, P Hjemdahl - Journal of Internal Medicine, 2022 - Wiley Online Library
Nonsteroidal anti‐inflammatory drugs (NSAIDs) inhibit the enzyme cyclooxygenase (COX),
which forms prostaglandins involved in pain and inflammation. COX inhibitors have …

Long‐term adverse effects of paracetamol–a review

JC McCrae, EE Morrison, IM MacIntyre… - British journal of …, 2018 - Wiley Online Library
Paracetamol (acetaminophen) is the most commonly used drug in the world, with a long
record of use in acute and chronic pain. In recent years, the benefits of paracetamol use in …

Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology

R Altman, B Bosch, K Brune, P Patrignani, C Young - Drugs, 2015 - Springer
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class
with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many …

Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs

N Moore, C Pollack, P Butkerait - Therapeutics and clinical risk …, 2015 - Taylor & Francis
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen have a long history of safe
and effective use as both prescription and over-the-counter (OTC) analgesics/antipyretics …

[HTML][HTML] The influence of non-steroidal anti-inflammatory drugs on the gut microbiome

MAM Rogers, DM Aronoff - Clinical Microbiology and Infection, 2016 - Elsevier
The composition of the gut microbiome with the use of non-steroidal anti-inflammatory drugs
(NSAIDs) has not been fully characterized. Drug use within the past 30 days was …

[HTML][HTML] OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research …

W Zhang, G Nuki, RW Moskowitz, S Abramson… - Osteoarthritis and …, 2010 - Elsevier
OBJECTIVE: To update evidence for available therapies in the treatment of hip and knee
osteoarthritis (OA) and to examine whether research evidence has changed from 31 …

Ibuprofen safety at the golden anniversary: are all NSAIDs the same? A narrative review

G Varrassi, JV Pergolizzi, P Dowling, A Paladini - Advances in therapy, 2020 - Springer
Ibuprofen first came to market about 50 years ago and rapidly moved to over-the-counter
(OTC) sales. In April 2019, the National Agency for the Safety of Medicines and Health …

[HTML][HTML] OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

W Zhang, RW Moskowitz, G Nuki, S Abramson… - Osteoarthritis and …, 2008 - Elsevier
PURPOSE: To develop concise, patient-focussed, up to date, evidence-based, expert
consensus recommendations for the management of hip and knee osteoarthritis (OA), which …

Pharmacological management of persistent pain in older persons

American Geriatrics Society Panel on the … - Pain …, 2009 - academic.oup.com
Pain is a complex phenomenon caused by noxious sensory stimuli or neuropathological
mechanisms. An individual's memories, expectations, and emotions modify the experience …

[HTML][HTML] OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of …

W Zhang, RW Moskowitz, G Nuki, S Abramson… - Osteoarthritis and …, 2007 - Elsevier
PURPOSE: As a prelude to developing updated, evidence-based, international consensus
recommendations for the management of hip and knee osteoarthritis (OA), the Osteoarthritis …